NovoCure Aktie [WKN DE: A140ML / ISIN: JE00BYSS4X48]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu NovoCure Limited

19.04.22		Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu (Businesswire)
08.04.22		Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)
01.04.22		Novocure to Report First Quarter 2022 Financial Results (Businesswire)
24.03.22		Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial (Businesswire)
23.03.22		Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer (Businesswire)
28.02.22		Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation (Businesswire)
24.02.22		Novocure’s General Counsel Resigns After 10 Years of Service (Businesswire)
24.02.22		New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response (Businesswire)
24.02.22		Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update (Businesswire)
01.07.21		Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer (Businesswire)
16.06.21		Novocure Initiates Usability Study for Flexible Torso Array (Businesswire)
25.05.21		Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma (Businesswire)
18.05.21		Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
29.04.21		Novocure Reports First Quarter 2021 Financial Results and Provides Company Update (Businesswire)
22.04.21		Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer (Businesswire)
15.04.21		Novocure gibt neueste Entwicklungen in der zulassungsrelevanten Phase-3-Studie LUNAR zu Tumor Treating Fields bei nicht-kleinzelligem Lungenkarzinom bekannt (Businesswire)
13.04.21		Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
09.04.21		Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)
01.04.21		Novocure to Report First Quarter 2021 Financial Results (Businesswire)
25.02.21		Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update (Businesswire)
08.02.21		Novocure Announces Addition to Its Board of Directors (Businesswire)
11.01.21		Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update (Businesswire)
23.12.20		Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference (Businesswire)
14.12.20		Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom (Businesswire)
14.12.20		Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
10.12.20		First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma (Businesswire)
25.11.20		Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference (Businesswire)
19.11.20		Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting (Businesswire)
16.11.20		Prüfungsausschuss beschließt Erstattung medizinischer Leistungen für Behandlung mit Tumor-Therapie-Feldern in Deutschland (Businesswire)
11.11.20		Novocure Receives CE Mark for NovoTTF-100L™ System (Businesswire)
10.11.20		Novocure Announces Agenda for Virtual Research and Development Day (Businesswire)
09.11.20		Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks (Businesswire)
05.11.20		Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement (Businesswire)
03.11.20		Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement (Businesswire)
02.11.20		Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes (Businesswire)
29.10.20		Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update (Businesswire)
29.10.20		Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research (Businesswire)
02.10.20		Novocure to Report Third Quarter 2020 Financial Results (Businesswire)
29.09.20		Novocure to Host Virtual Research & Development Day (Businesswire)
25.09.20		Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community (Businesswire)
04.09.20		Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference (Businesswire)
13.08.20		Novocure Announces Expansion of Its Executive Leadership Team (Businesswire)
30.07.20		Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update (Businesswire)
28.07.20		Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
22.07.20		First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays (Businesswire)
15.07.20		Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer (Businesswire)
08.07.20		Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™ (Businesswire)
07.07.20		Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer (Businesswire)
01.07.20		Novocure to Report Second Quarter 2020 Financial Results (Businesswire)
02.06.20		Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

EQS-Adhoc: STRABAG SE CEO Klemens Haselsteiner passed away completely unexpectedly

Ripple auf dem Weg zu 100 US-Dollar in 2025?

Ripple Kurs Prognose: 10 US-Dollar bis Ende des Jahres?

EQS-Adhoc: STRABAG SE-Vorstandsvorsitzender Klemens Haselsteiner völlig überraschend verstorben

Auric Minerals-Aktie: Kurssturz wegen neuem Vertrag?

Intel-Aktie zieht an: Übernahmegerüchte und neue Strategie mit Abspaltungen im Fokus

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	19.01.2025 09:31
Kaufwert:	EUR
	Hinzufügen Speichern